GB9206757D0
(en)
|
1992-03-27 |
1992-05-13 |
Ferring Bv |
Novel peptide receptor ligands
|
US6074642A
(en)
|
1994-05-02 |
2000-06-13 |
Alexion Pharmaceuticals, Inc. |
Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
|
US5628984A
(en)
|
1995-07-31 |
1997-05-13 |
University Of North Carolina At Chapel Hill |
Method of detecting lung disease
|
US6319897B1
(en)
|
1996-03-13 |
2001-11-20 |
John D. Lambris |
Peptides which inhibit complement activation
|
WO1998055471A1
(en)
|
1997-06-03 |
1998-12-10 |
Biocryst Pharmaceuticals, Inc. |
Novel compounds useful in the complement, coagulat and kallikrein pathways and method for their preparation
|
CA2325638A1
(en)
|
1998-03-26 |
1999-09-30 |
Hideki Yamada |
Amide derivatives and nociceptin antagonists
|
DE69910045T2
(de)
|
1998-09-09 |
2004-04-22 |
Metabasis Therapeutics Inc., San Diego |
Neue heteroaromatische fructose 1,6-bisphosphatase inhibitoren
|
KR20000047461A
(ko)
|
1998-12-29 |
2000-07-25 |
성재갑 |
트롬빈 억제제
|
WO2001017980A1
(fr)
|
1999-09-03 |
2001-03-15 |
Ajinomoto Co., Inc. |
Nouveaux procedes de preparation de derives d'oxazepine
|
US7528165B2
(en)
|
2001-12-13 |
2009-05-05 |
National Health Research Institutes |
Indole compounds
|
ITMI20021527A1
(it)
|
2002-07-11 |
2004-01-12 |
Consiglio Nazionale Ricerche |
Anticorpi anti componente c5 del complemento e loro uso
|
WO2004007501A1
(en)
|
2002-07-16 |
2004-01-22 |
Amura Therapeutics Limited |
Biologically active compounds
|
EP2311480B1
(en)
|
2002-09-20 |
2013-06-26 |
The Trustees of The University of Pennsylvania |
Compstatin analogs with improved activity
|
FR2845382A1
(fr)
|
2002-10-02 |
2004-04-09 |
Sanofi Synthelabo |
Derives d'indazolecarboxamides, leur preparation et leur utilisation en therapeutique
|
US7632858B2
(en)
|
2002-11-15 |
2009-12-15 |
Bristol-Myers Squibb Company |
Open chain prolyl urea-related modulators of androgen receptor function
|
AU2003902946A0
(en)
|
2003-06-12 |
2003-06-26 |
Fujisawa Pharmaceutical Co., Ltd. |
Dpp-iv inhibitor
|
US7482376B2
(en)
|
2003-07-03 |
2009-01-27 |
3-Dimensional Pharmaceuticals, Inc. |
Conjugated complement cascade inhibitors
|
PT1713503E
(pt)
|
2004-02-10 |
2013-11-14 |
Nat Jewish Health |
Inibição do factor b, a via alternativa do complemento e métodos relacionados
|
MXPA06010756A
(es)
|
2004-03-24 |
2006-12-15 |
Jerini Ag |
Nuevos compuestos para la inhibicion de la angiogenesis y su uso.
|
ES2435398T3
(es)
|
2004-04-08 |
2013-12-19 |
Eye Co Pty Ltd. |
Tratamiento de retinopatía exudativa con mineralocorticoides
|
US7417063B2
(en)
|
2004-04-13 |
2008-08-26 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles useful as serine protease inhibitors
|
US20080075728A1
(en)
|
2004-07-20 |
2008-03-27 |
Walter Newman |
Combination Therapies Of Hmgb And Complement Inhibitors Against Inflammation
|
US8168584B2
(en)
|
2005-10-08 |
2012-05-01 |
Potentia Pharmaceuticals, Inc. |
Methods of treating age-related macular degeneration by compstatin and analogs thereof
|
DK1960422T3
(da)
|
2005-11-28 |
2012-08-13 |
Univ Pennsylvania |
Meget virksomme compstatin-analoger
|
RU2008128452A
(ru)
|
2005-12-12 |
2010-01-20 |
Дженелабс Текнолоджис, Инк. (Us) |
Соединения n-(6-членных арил)-амидов, фармацевтическая композиция с противовирусной активностью на их основе, способ лечения или профилактики вирусной инфекции с их помощью и способ их получения
|
US20090220508A1
(en)
|
2006-03-15 |
2009-09-03 |
Alexion Pharmaceuticals, Inc. |
Treatment Of Paroxysmal Nocturnal Hemoglobinuria Patients By An Inhibitor Of Complement
|
EP2108642A1
(en)
|
2006-10-17 |
2009-10-14 |
Kyowa Hakko Kirin Co., Ltd. |
Jak inhibitor
|
KR20090109551A
(ko)
|
2007-01-15 |
2009-10-20 |
산텐 세이야꾸 가부시키가이샤 |
IκB 키나아제 β 저해 활성을 갖는 신규 인돌 유도체
|
EP2979729A3
(en)
|
2007-02-05 |
2016-05-11 |
Apellis Pharmaceuticals, Inc. |
Compstatin analogues for use in the treatment of inflammatory conditions of the respiratory system
|
TWI388334B
(zh)
|
2007-12-11 |
2013-03-11 |
Glaxo Group Ltd |
抗原結合蛋白質
|
US8524716B2
(en)
|
2007-12-24 |
2013-09-03 |
Janssen R&D Ireland |
Macrocyclic indoles as hepatitis C virus inhibitors
|
WO2009091826A2
(en)
|
2008-01-14 |
2009-07-23 |
The Board Of Regents Of The University Of Texas System |
Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)
|
CN102170906B
(zh)
|
2008-08-05 |
2014-07-30 |
诺华股份有限公司 |
靶定补体蛋白c5的抗体的组合物和方法
|
EP2391419B1
(en)
|
2009-01-29 |
2019-06-12 |
ForSight Vision4, Inc. |
Posterior segment drug delivery
|
NO2424557T3
(es)
|
2009-05-01 |
2018-03-24 |
|
|
WO2010135717A2
(en)
|
2009-05-21 |
2010-11-25 |
Potentia Pharmaceuticals, Inc. |
Complement assays and uses thereof
|
JP5758298B2
(ja)
|
2009-10-16 |
2015-08-05 |
持田製薬株式会社 |
非アルコール性脂肪肝炎関連マーカー
|
WO2011057158A1
(en)
|
2009-11-05 |
2011-05-12 |
Taligen Therapeutics, Inc. |
Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
|
CN102906092B
(zh)
|
2009-12-31 |
2016-08-03 |
和记黄埔医药(上海)有限公司 |
某些***并吡啶化合物和***并吡嗪化合物、其组合物和其使用方法
|
SG184832A1
(en)
|
2010-04-16 |
2012-11-29 |
Ac Immune Sa |
Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
|
WO2011163394A2
(en)
|
2010-06-22 |
2011-12-29 |
Apellis Pharmaceuticals, Inc. |
Compstatin analogs for treatment of neuropathic pain
|
WO2012006599A2
(en)
|
2010-07-09 |
2012-01-12 |
Apellis Pharmaceuticals, Inc. |
Compstatin analogs for treatment of rhinosinusitis and nasal polyposis
|
US9085555B2
(en)
|
2011-01-04 |
2015-07-21 |
Novartis Ag |
Complement pathway modulators and uses thereof
|
AU2012253294B2
(en)
|
2011-05-11 |
2017-07-20 |
Apellis Pharmaceuticals, Inc. |
Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof
|
US8809313B2
(en)
|
2011-05-27 |
2014-08-19 |
Achillion Pharmaceuticals, Inc. |
Substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes useful for treating HCV infections
|
WO2012177782A1
(en)
|
2011-06-20 |
2012-12-27 |
Myrexis, Inc. |
Compounds and therapeutic uses thereof
|
WO2012178083A1
(en)
|
2011-06-22 |
2012-12-27 |
Apellis Pharmaceuticals, Inc. |
Methods of treating chronic disorders with complement inhibitors
|
US20130035392A1
(en)
|
2011-08-01 |
2013-02-07 |
Mcgeer Patrick L |
Selective inhibition of the membrane attack complex of complement and C3 convertase by low molecular weight components of the aurin tricarboxylic acid synthetic complex
|
DK2753636T3
(da)
|
2011-09-07 |
2020-02-03 |
Univ Pennsylvania |
Compstatinanaloger med forbedret farmakokinetiske egenskaber
|
NZ728721A
(en)
|
2012-05-03 |
2018-05-25 |
Kala Pharmaceuticals Inc |
Pharmaceutical nanoparticles showing improved mucosal transport
|
US9056874B2
(en)
|
2012-05-04 |
2015-06-16 |
Novartis Ag |
Complement pathway modulators and uses thereof
|
CN115040653A
(zh)
|
2012-06-18 |
2022-09-13 |
奥默罗斯公司 |
抑制masp-1和/或masp-2和/或masp-3的组合物和方法
|
WO2013192345A1
(en)
|
2012-06-20 |
2013-12-27 |
Novartis Ag |
Complement pathway modulators and uses thereof
|
US9579360B2
(en)
|
2012-06-20 |
2017-02-28 |
The Trustees Of The University Of Pennsylvania |
Methods of treating or preventing periodontitis and diseases associated with periodontitis
|
EP2867222A1
(en)
|
2012-06-28 |
2015-05-06 |
Novartis AG |
Pyrrolidine derivatives and their use as complement pathway modulators
|
US9468661B2
(en)
|
2012-06-28 |
2016-10-18 |
Novartis Ag |
Pyrrolidine derivatives and their use as complement pathway modulators
|
ES2648962T3
(es)
|
2012-06-28 |
2018-01-09 |
Novartis Ag |
Derivados de pirrolidina y su uso como moduladores de la vía del complemento
|
US9487483B2
(en)
|
2012-06-28 |
2016-11-08 |
Novartis Ag |
Complement pathway modulators and uses thereof
|
EP2867226B1
(en)
|
2012-06-28 |
2018-11-14 |
Novartis AG |
Complement pathway modulators and uses thereof
|
US9388199B2
(en)
|
2012-06-28 |
2016-07-12 |
Novartis Ag |
Pyrrolidine derivatives and their use as complement pathway modulators
|
WO2014002059A1
(en)
|
2012-06-29 |
2014-01-03 |
Novartis Ag |
CRYSTALLINE FORMS OF 1-(2-((1R,3S,5R)-3-(((R)-1-(3-chloro-2-fluorophenyl)ethyl)carbamoyl)-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-1Hpyrazolo[3,4-c]pyridine-3-carboxamide
|
WO2014005150A1
(en)
|
2012-06-29 |
2014-01-03 |
Novartis Ag |
Crystalline forms of l-(2-((lr,3s,5r)-3-( (2 -fluoro-3 - (trifluoromethoxy) phenyl) carbamoyl) - 2 -azabicycl o [3.1.0] hexan- 2 -yl) - 2 -oxoethyl) - 5 -methyl - 1h - pyrazolo [3, 4 -c] pyridine - 3 - carboxami de and salts thereof
|
KR20150036481A
(ko)
|
2012-07-12 |
2015-04-07 |
노파르티스 아게 |
보체 경로 조절제 및 그의 용도
|
WO2014037480A1
(en)
|
2012-09-10 |
2014-03-13 |
F. Hoffmann-La Roche Ag |
6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
|
RS62243B9
(sr)
|
2012-11-15 |
2022-11-30 |
Apellis Pharmaceuticals Inc |
Analozi kompstatina sa produženim trajanjem dejstva i njihove kompozicije i postupci
|
US20160194359A1
(en)
|
2012-11-15 |
2016-07-07 |
Apellis Pharmaceuticals, Inc. |
Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
|
JP6563815B2
(ja)
|
2013-01-23 |
2019-08-21 |
エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント |
天然抗体に由来する構築物を標的化すること及びその使用
|
US9475806B2
(en)
|
2013-03-14 |
2016-10-25 |
Novartis Ag |
Complement factor B inhibitors and uses there of
|
US10308687B2
(en)
|
2013-03-15 |
2019-06-04 |
Apellis Pharmaceuticals, Inc. |
Cell-penetrating compstatin analogs and uses thereof
|
JP2016169161A
(ja)
|
2013-07-19 |
2016-09-23 |
大日本住友製薬株式会社 |
新規イミダゾピリジン化合物
|
EP3290922A1
(en)
|
2013-08-07 |
2018-03-07 |
Alexion Pharmaceuticals, Inc. |
Atypical hemolytic uremic syndrome (ahus) biomarker proteins
|
US20150104445A1
(en)
|
2013-10-10 |
2015-04-16 |
Viropharma Holdings Limited |
Methods of inhibiting the alternative pathway of complement immune system activation and compositions used therein
|
CA2940777A1
(en)
*
|
2014-02-25 |
2015-09-03 |
Achillion Pharmaceuticals, Inc. |
Compounds for treatment of complement mediated disorders
|
WO2017035418A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Disubstituted compounds for treatment of immune and inflammatory disorders
|
WO2017035362A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Use of complement pathway inhibitor compounds to mitigate adoptive t-cell therapy associated adverse immune responses
|
US10385097B2
(en)
|
2015-08-26 |
2019-08-20 |
Achillion Pharmaceuticals, Inc. |
Ether compounds for treatment of medical disorders
|
AR106018A1
(es)
|
2015-08-26 |
2017-12-06 |
Achillion Pharmaceuticals Inc |
Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
|
WO2017035411A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Ether compounds for treatment of immune and inflammatory disorders
|
WO2017035352A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Carbamate, ester, and ketone compounds for treatment of medical disorders
|
WO2017035415A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Alkyne compounds for treatment of immune and inflammatory disorders
|
WO2017035361A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Disubstituted compounds for the treatment of medical disorders
|
AR105808A1
(es)
|
2015-08-26 |
2017-11-08 |
Achillion Pharmaceuticals Inc |
Compuestos de amida para el tratamiento de trastornos médicos
|
AR105809A1
(es)
|
2015-08-26 |
2017-11-08 |
Achillion Pharmaceuticals Inc |
Compuestos para el tratamiento de trastornos médicos
|
WO2017035351A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Amino compounds for treatment of medical disorders
|
WO2017035405A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Amino compounds for treatment of immune and inflammatory disorders
|
WO2017035357A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Phosphonate compounds for treatment of medical disorders
|
WO2017035401A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Amide compounds for treatment of immune and inflammatory disorders
|
WO2017035417A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Phosphonate compounds for treatment of immune and inflammatory disorders
|
WO2017035409A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
|
EP3340982B1
(en)
|
2015-08-26 |
2021-12-15 |
Achillion Pharmaceuticals, Inc. |
Compounds for treatment of immune and inflammatory disorders
|
WO2017035348A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Alkyne compounds for treatment of medical disorders
|
WO2017035413A2
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Carbamate, ester, and ketone compounds for treatment of immune and inflammatory disorders
|
US20190127366A1
(en)
|
2015-12-11 |
2019-05-02 |
Lifesci Pharmaceuticals, Inc. |
Therapeutic inhibitory compounds
|
JP7339733B2
(ja)
|
2016-01-14 |
2023-09-06 |
ケモセントリックス,インコーポレイティド |
C3腎症を処置する方法
|
AU2017210042B2
(en)
|
2016-01-20 |
2021-01-21 |
396419 B.C. Ltd. |
Compositions and methods for inhibiting Factor D
|
TW202222786A
(zh)
|
2016-02-01 |
2022-06-16 |
美商百歐克斯製藥公司 |
苯并吡唑化合物及其類似物
|
JP7057290B2
(ja)
|
2016-06-27 |
2022-04-19 |
アキリオン ファーマシューティカルズ,インコーポレーテッド |
医学的障害を治療するためのキナゾリン及びインドール化合物
|
JOP20170154B1
(ar)
|
2016-08-01 |
2023-03-28 |
Omeros Corp |
تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة
|
KR102632860B1
(ko)
|
2017-03-01 |
2024-02-02 |
아칠리온 파르마세우티칼스 인코포레이티드 |
의학적 장애의 치료를 위한 아릴, 헤테로아릴, 및 헤테로사이클릭 약학적 화합물
|
WO2018160891A1
(en)
|
2017-03-01 |
2018-09-07 |
Achillion Pharmaceutical, Inc. |
Pharmaceutical compounds for treatment of medical disorders
|
WO2018160892A1
(en)
|
2017-03-01 |
2018-09-07 |
Achillion Pharmaceuticals, Inc. |
Macrocyclic compounds for treatment of medical disorders
|
CN111163767A
(zh)
|
2017-08-02 |
2020-05-15 |
艾其林医药公司 |
治疗阵发性睡眠性血红蛋白尿症的治疗方案
|
JP2020536097A
(ja)
|
2017-10-04 |
2020-12-10 |
アレクシオン ファーマシューティカルズ, インコーポレイテッド |
膜性増殖性糸球体腎炎患者の処置のための抗c5抗体の投薬量および投与
|
US11759472B2
(en)
|
2017-11-21 |
2023-09-19 |
Cs Pharmaceuticals Limited |
Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface
|
WO2019211799A1
(en)
|
2018-05-03 |
2019-11-07 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
|
EP3856164A4
(en)
|
2018-09-25 |
2022-07-13 |
Achillion Pharmaceuticals, Inc. |
MORPHIC FORMS OF COMPLEMENT FACTOR D INHIBITORS
|
WO2020109343A1
(en)
|
2018-11-29 |
2020-06-04 |
F. Hoffmann-La Roche Ag |
Combination therapy for treatment of macular degeneration
|
JP7471300B2
(ja)
|
2018-12-17 |
2024-04-19 |
アキリオン ファーマシューティカルズ, インコーポレーテッド |
補体介在性疾患を治療するための的を絞った投与
|
EP4003327A4
(en)
|
2019-07-31 |
2023-08-02 |
Biocryst Pharmaceuticals, Inc. |
DOSING REGIME FOR ORAL COMPLEMENT FACTOR-D INHIBITORS
|